| Discovery and clinical introduction of first-in-class imipridone ONC201 JE Allen, CLB Kline, VV Prabhu, J Wagner, J Ishizawa, N Madhukar, ... Oncotarget 7 (45), 74380, 2016 | 138 | 2016 |
| Targeting TRAIL in the treatment of cancer: new developments B Lim, JE Allen, VV Prabhu, MK Talekar, NK Finnberg, WS El-Deiry Expert opinion on therapeutic targets 19 (9), 1171-1185, 2015 | 111 | 2015 |
| The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). S Maude, G Hucks, A Seif, M Talekar, D Teachey, D Baniewicz, ... J Clin Oncol 35, 2017 (suppl; abstr 103), 2017 | 84 | 2017 |
| Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia SL Maude, DM Barrett, SR Rheingold, R Aplenc, DT Teachey, C Callahan, ... Blood 128 (22), 217, 2016 | 76 | 2016 |
| Understanding the differences between oncology patients and oncology health professionals concerning Spirituality/Religiosity: a cross-sectional study MS Camargos, Mayara Goulart de RN, PD Paiva, Carlos Eduardo MD, ... Medicine 94 (47), 2015 | 49 | 2015 |
| Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10 JE Allen, VV Prabhu, M Talekar, APJ Van Den Heuvel, B Lim, DT Dicker, ... Cancer research 75 (8), 1668-1674, 2015 | 46 | 2015 |
| DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM) A Nooka, K Stockerl-Goldstein, H Quach, A Forbes, MV Mateos, A Khot, ... ASCO Annual Meeting 2020, 2020 | 44 | 2020 |
| DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple … R Popat, A Nooka, K Stockerl-Goldstein, R Abonour, R Ramaekers, ... Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020 | 38 | 2020 |
| Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies VV Prabhu, MK Talekar, AR Lulla, CLB Kline, L Zhou, J Hall, ... Cell Cycle 17 (4), 468-478, 2018 | 37 | 2018 |
| A multicenter study of bacterial blood stream infections in pediatric allogeneic hematopoietic cell transplantation recipients: the role of acute gastrointestinal graft-versus … P Satwani, JL Freedman, S Chaudhury, Z Jin, A Levinson, MD Foca, ... Biology of blood and marrow transplantation 23 (4), 642-647, 2017 | 35 | 2017 |
| ONC201 Induces Cell Death in Pediatric non-Hodgkin's Lymphoma Cells M Talekar, J Allen, D Dicker, W El-Deiry Cell Cycle, 2015 | 31 | 2015 |
| Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL) M Talekar, S Maude, G Hucks, L Motley, C Callahan, C White, ... J Clin Oncol 35, 2017 (suppl; abstr 1050), 2017 | 17 | 2017 |
| Potassium changes associated with blood transfusion in pediatric patients J Olson, M Talekar, M Sachdev, W Castellani, N De la Cruz, J Davis, ... American journal of clinical pathology 139 (6), 800-805, 2013 | 17 | 2013 |
| A case of severe chlorite poisoning successfully treated with early administration of methylene blue, renal replacement therapy, and red blood cell transfusion: case report A Gebhardtova, P Vavrinec, D Vavrincova-Yaghi, M Seelen, A Dobisova, ... Medicine 93 (9), 2014 | 16 | 2014 |
| Immune reconstitution after hematopoietic stem cell transplantation MK Talekar, T Olson Hematopoietic stem cell transplantation for the pediatric hematologist …, 2018 | 14 | 2018 |
| DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed/refractory multiple … RM Rifkin, K Boyd, S Grosicki, K Kim, F Di Raimondo, MA Dimopoulos, ... Blood 136, 53-54, 2020 | 13 | 2020 |
| DREAMM 4: a phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab … S Trudel, A Nooka, D Fecteau, M Talekar, RC Jewell, D Williams, J Evans, ... Annals of Oncology 30, v447, 2019 | 11 | 2019 |
| Clinicopathological features and prognostic factors of young patients with surgically treated liver cancer W Zhang, R Jiang, J Hou, B Sun Medicine 94 (12), 2015 | 11 | 2015 |
| Congenital self-healing reticulohistiocytosis YH Lee, MK Talekar, CG Chung, MD Bell, AL Zaenglein The Journal of Clinical and Aesthetic Dermatology 7 (2), 49, 2014 | 11 | 2014 |
| Phase I/II, Open-label, 2-Arm Study to Evaluate Safety, Tolerability and Clinical Activity of GSK2857916 in Combination with 2 Standard-of-Care (SoC) Regimens in Relapsed … LJ Costa, H Quach, K Stockerl-Goldstein, B Augustson, G Ferron-Brady, ... ASCO 2019, 2019 | 8 | 2019 |
Joshua E AllenOncoceuticsPotvrđena adresa e-pošte na oncoceutics.com
